Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals
The American Journal of MedicinePublished 1 February 1996
Gordon Schectman, Jan Hiatt
Citations165
SJR quartileQ1
SJR score1.00
SNIP1.04
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Multivariate analysis indicated that lower baseline LDL-C and triglycerides, use of combinations of drug therapy rather than monotherapy, and patient adherence to treatment predicted the achievement of goal lipid levels.
Abstract
Successful implementation of NCEP guidelines, frequently requires combination drug therapies, and is limited by poor patient tolerance and acceptance of niacin and the sequestrants.
Keywords
MedicineEconomics, Econometrics and Finance
Clinical ChemistryEstimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge
32,475 Citations1972William T. Friedewald, Robert I. Levy +1 more
A method for estimating the cholesterol content of the serum low-density lipoprotein fraction (Sf0-20) is presented and comparison of this suggested procedure with the more direct procedure, in which the ultracentrifuge is used, yielded correlation coefficients of .94 to .99.
JAMASummary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
27,886 Citations1993Scott M. Grundy
Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
Clinical ChemistryEnzymatic Determination of Total Serum Cholesterol
9,168 Citations1974Charles C. Allain, Lucy S Poon +3 more
An enzymatic method is described for determination of total serum cholesterol by use of a single aqueous reagent and has excellent precision.
New England Journal of MedicineRegression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B
2,166 Citations1990Greg Brown, John J. Albers +8 more
In men with coronary artery disease who were at high risk for cardiovascular events, intensive lipid-lowering therapy reduced the frequency of progression of coronary lesions, increased the frequencyof regression, and reduced the incidence of cardiovascular events.
New England Journal of MedicineEffect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia
1,008 Citations1990Hēnry Buchwald, Richard L. Varco +22 more
Significant evidence is provided supporting the beneficial effects of lipid modification in the reduction of atherosclerosis progression and sustained improvement in the blood lipid patterns of patients who have had a myocardial infarction and reduces their subsequent morbidity due to coronary heart disease.
CirculationLipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease.
822 Citations1993B. Greg Brown, Xiaohui Zhao +2 more
The composite of data presented here supports the hypothesis that lipid-lowering therapy selectively depletes that relatively small but dangerous subgroup of fatty lesions containing a large lipid core and dense clusters of intimal macrophages, which are effectively stabilized and clinical event rate is accordingly decreased.
JAMARegression of Coronary Atherosclerosis During Treatment of Familial Hypercholesterolemia With Combined Drug Regimens
801 Citations1990John P. Kane
Reduction of low-density lipoprotein cholesterol levels can induce regression of atherosclerotic lesions of the coronary arteries in patients with familial hypercholesterolemia, and the anticipation of benefit from treatment applies to women and men alike.
JAMABeneficial Effects of Colestipol-Niacin on Coronary Atherosclerosis
488 Citations1990Linda Cashin-Hemphill
A subgroup of 103 subjects treated for 4 years of combined colestipol-niacin therapy reaffirm the need for early initiation of vigorous long-term lipid lowering therapy in coronary bypass subjects and indicate that regression can continue for4 years.
New England Journal of MedicineThe Value of Lowering Cholesterol after Myocardial Infarction
417 Citations1990Jacques E. Rossouw, B. Lewis +1 more
Recommendations for lowering the cholesterol level to prevent coronary heart disease have focused largely on primary prevention and have paid less attention to the issue of lowering cholesterol in patients who already have coronary disease.
Clinical ChemistryQuantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2.
397 Citations1983Gerd Assmann, H Schriewer +2 more
A modified phosphotungstic acid/MgCl2 precipitation procedure for the precipitation of apolipoprotein B-containing lipoproteins is complete, with negligible coprecipitation of high-density lipoprotein subfractions (HDL1, HDL2, HDL3), even in hypertriglyceridemic sera.
New England Journal of MedicineDiscontinuation of Antihyperlipidemic Drugs — Do Rates Reported in Clinical Trials Reflect Rates in Primary Care Settings?
380 Citations1995Susan E. Andrade, Alexander M. Walker +5 more
The effectiveness and tolerability of antihyperlipidemic medications should be studied further in populations that typically use the agents, and in open-label studies were similar to those in the HMOs.
The American Journal of CardiologyEfficacy and long-term adverse effect pattern of lovastatin
339 Citations1988Jonathan A. Tobert
The good adverse-effect profile of lovastatin is supported both by a substantial body of data in patients treated for over 2 years in clinical trials, and by experience in clinical use with a large number of patients since the drug has been available for prescription.
Medical CareThe Inaccuracy in Using Interviews to Estimate Patient Reliability in Taking Medications at Home
159 Citations1969Leon Gordis, Milton Markowitz +1 more
An important part of the medical care of many chronically-ill patients is self-administration of oral medications at home over a long period of time.
Annals of Internal MedicineLovastatin, Nicotinic Acid, and Rhabdomyolysis
148 Citations1988Peter D. Reaven, Joseph L. Witztum
A case of severe rhabdomyolysis in a patient being treated with lovastatin and nicotinic acid is observed, which may be both instructive and benefic...
Clinical ChemistryManual and continuous-flow colorimetry of triacylglycerols by a fully enzymic method.
138 Citations1979R E Megraw, Dorothy E Dunn +1 more
The procedure is sensitive, has good precision and accuracy, and gives results that compare well with chemical and enzymic commercial kit methods.
Archives of Internal MedicineMeasurement of Medication Compliance in a Clinical Setting
99 Citations1979Suzanne W. Fletcher
Interview may be the most useful methof of measuring medication compliance in clinical practice and is correlated with SDCs, pill counts did not.
The American Journal of CardiologyFluvastatin with and without niacin for hypercholesterolemia
90 Citations1994Terry A. Jacobson, Margaret M. Chin +3 more
Although the fluvastatin-niacin combination in this study was without evidence of significant transaminitis, myopathy, or rhabdomyolysis, it would seem prudent to continue to monitor its safety with longer term use.
The American Journal of CardiologyComparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia
85 Citations1994Jean Davignon, Ghislaine O. Roederer +10 more
Pravastatin is very effective and well tolerated in the treatment of type IIa or IIb primary hypercholesterolemia, and is superior to nicotinic acid in both efficacy and adverse event profile.
CirculationExpanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins.
82 Citations1992Charles L. Shear, Frank A. Franklin +6 more
In patients with initially high levels of triglycerides and low levels of HDL cholesterol, the elevation of LDL cholesterol produced by lovastatin appears to be enhanced, and patient characteristics had very little impact of clinical importance on the dose-dependent LDL cholesterol lowering found with Lovastatin.
The American Journal of CardiologyComparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia
80 Citations1993Jc. Daubresse
There was no significant difference between groups in the frequency of drug-related adverse experiences and the efficacy goal of LDL cholesterol < 130 mg/dl was achieved in 65% of the patients treated with simvastatin versus 39% of those treated with pravastatin.
JAMAPrescribed Use of Cholesterol-Lowering Drugs in the United States, 1978 Through 1988
72 Citations1990Diane K. Wysowski
Data from two pharmaceutical marketing research databases were used to study trends in outpatient use of cholesterol-lowering drugs in the United States from 1978 through 1988, showing a fivefold increase between 1983 and 1988 and the introduction and use of two new drugs, gemfibrozil and lovastatin.
The American Journal of CardiologyA multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia
55 Citations1993The Lovastatin Pravastatin Study Group∗
Across the recommended dosage ranges, lovastatin was more effective than pravastatin in reducing total and LDL cholesterol; however, both agents had similar safety profiles.
Annals of Internal MedicineLow-Dose Combined Therapy with Fluvastatin and Cholestyramine in Hyperlipidemic Patients
54 Citations1994Dennis L. Sprecher, Jonathan Abrams +8 more
The LDL cholesterol-lowering efficacy of various combinations of low-dose resin and statin treatments, using cholestyramine (Questran Light; Bristol) and fluvastatin, is evaluated.
The American Journal of CardiologyEvaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans
50 Citations1993Gordon Schectman, Jan Hiatt +1 more
Niacin and lovastatin are effective drugs for hypercholesterolemia management in the Veterans Administration Medical Center setting and may differ from that measured in randomized controlled trials.
The American Journal of CardiologyEnhanced low density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy
46 Citations1995Helmut G. Schrott, Evan A. Stein +6 more
Results demonstrate that the combination of low-dose lovastatin (20 mg/day) with low- dose colestipol (5 or 10 g/ day) produces LDL cholesterol reductions equal to or greater than higher doses of lovASTatin (40 mg/ day).
New England Journal of MedicineRegression of Coronary Atherosclerosis
42 Citations1990J Loscalzo
The study of therapeutic interventions to bring about the regression of atherosclerosis in other vertebrates, including birds, swine, dogs, and nonhuman primates, confirms that the ability to induce regression depends on the animal.
Archives of Internal MedicineEfficacy of Low-Dose Cholesterol-Lowering Drug Therapy in Men With Moderate Hypercholesterolemia
31 Citations1995Margo A. Denke
Low-dose combination drug therapy for the management of hypercholesterolemia appears to be an effective means of lowering cholesterol levels that remain persistently elevated after dietary therapy, at the same time, it should carry a low risk of toxic effects.
PubMedCombination drug therapy for hypercholesterolemia. The trade-off between cost and simplicity.
13 Citations1993Gustavo R. Heudebert, Jerome Van Ruiswyk +2 more
Archives of Internal MedicineCombination Drug Therapy for Hypercholesterolemia
11 Citations1993Gustavo R. Heudebert
Fulfillment of the target LDL-C approach recommended by the National Cholesterol Education Program often requires the use of multiple drugs, and when lovastatin is used initially, the regimen becomes simpler, albeit more expensive.